Skip to main content

Search Videos and More

Showing 13 - 24 of 41 results

Previous| 1 | 2 | 3 ...4 |Next

Once you begin thyroid hormone replacement therapy, how is that patient followed clinically to ensure treatment success? What are the recommended starting doses? How do you titrate the dose over time?

Once you begin thyroid hormone replacement therapy, how is that patient followed clinically to ensure treatment success? What are the recommended starting doses? How do you titrate the dose over time?

Once you decide to treat, in order to address the full treatment “outcome” equation—that is, achieving both laboratory (TSH, T4) targets and symptomatic/quality-of-life goals—how do you construct your therapeutic regimen?

Once you decide to treat, in order to address the full treatment “outcome” equation—that is, achieving both laboratory (TSH, T4) targets and symptomatic/quality-of-life goals—how do you construct your therapeutic regimen?

In primary care/internal medicine, combination therapy typically consists of DTE as the preferred approach in patients failing to respond to LT4 monotherapy. Can you provide a roadmap for DTE use—including NP Thyroid and other formulations?

In primary care/internal medicine, combination therapy typically consists of DTE as the preferred approach in patients failing to respond to LT4 monotherapy. Can you provide a roadmap for DTE use—including NP Thyroid and other formulations?

Can you summarize the current role of DTE in managing persons with hypothyroidism, and the approach to identifying the 10%-20% of persons on LT4 monotherapy who, because of symptomatic shortfalls, may be appropriate for combination therapy?

Can you summarize the current role of DTE in managing persons with hypothyroidism, and the approach to identifying the 10%-20% of persons on LT4 monotherapy who, because of symptomatic shortfalls, may be appropriate for combination therapy?

Once you’ve determined that LT4 therapy is not achieving the desired symptomatic end points, what are the practical aspects of initiating DTE therapy in the PCP setting? What does the DTE roadmap look like for NP Thyroid® and other DTE formulations?

Once you’ve determined that LT4 therapy is not achieving the desired symptomatic end points, what are the practical aspects of initiating DTE therapy in the PCP setting? What does the DTE roadmap look like for NP Thyroid® and other DTE formulations?

How does the peripheral metabolism—the conversion or compromised conversion of T4 to T3—affect a patient’s response to T4 monotherapy? How does that set the stage for combination T4 plus T3 therapy in appropriately selected patients?

How does the peripheral metabolism—the conversion or compromised conversion of T4 to T3—affect a patient’s response to T4 monotherapy? How does that set the stage for combination T4 plus T3 therapy in appropriately selected patients?

The recognition that LT4 monotherapy is inadequate for producing symptomatic improvement in many patients has led to the formation of an international working group focused on identifying such patients. Can you share your experience with this group?

The recognition that LT4 monotherapy is inadequate for producing symptomatic improvement in many patients has led to the formation of an international working group focused on identifying such patients. Can you share your experience with this group?

Can you summarize the current treatment challenges for hypothyroidism as encountered by a broad spectrum of clinicians, including primary care, internal medicine, endocrine, women’s health, and geriatric specialists?

Can you summarize the current treatment challenges for hypothyroidism as encountered by a broad spectrum of clinicians, including primary care, internal medicine, endocrine, women’s health, and geriatric specialists?

What practical advice would you give to physicians who are not familiar with the specifics of how to initiate and/or monitor therapy with DTE? Are conversion tables available? Is there data to suggest which approach is better—DTE or T4/T3 (Cytomel)?

What practical advice would you give to physicians who are not familiar with the specifics of how to initiate and/or monitor therapy with DTE? Are conversion tables available? Is there data to suggest which approach is better—DTE or T4/T3 (Cytomel)?

Do you recommend measuring T3 levels in patients who are not satisfied with or symptomatically burdened after being launched on T4? What factors support a decision to embark on combination T4/T3 therapy, either by adding T3 or treating with DTE?

Do you recommend measuring T3 levels in patients who are not satisfied with or symptomatically burdened after being launched on T4? What factors support a decision to embark on combination T4/T3 therapy, either by adding T3 or treating with DTE?

What laboratory and/or clinical features, especially persistent symptoms, suggest the need for combination therapy—including with a DTE—to optimize management? What have trials evaluating patient preferences suggested about combination therapy?

What laboratory and/or clinical features, especially persistent symptoms, suggest the need for combination therapy—including with a DTE—to optimize management? What have trials evaluating patient preferences suggested about combination therapy?

Once you decide on combination therapy, what are the practical strategies—specifically, approved drug formulations, whether it be synthetic T3 (Cytomel) or DTE—that clinicians should consider at the front lines of care for hypothyroidism?

Once you decide on combination therapy, what are the practical strategies—specifically, approved drug formulations, whether it be synthetic T3 (Cytomel) or DTE—that clinicians should consider at the front lines of care for hypothyroidism?

Showing 13 - 24 of 41 results

Previous| 1 | 2 | 3 ...4 |Next